Is Sudarshan Pharma overvalued or undervalued?

As of 4 November 2025, Sudarshan Pharma's valuation grade has moved from attractive to fair. The company appears to be fairly valued at this time. Key ratios include a PE Ratio of 42.39, an EV to EBITDA of 22.76, and a ROE of 12.65%.
In comparison to peers, Sudarshan Pharma's PE Ratio is higher than Cipla's 22.35, which is rated attractive, but lower than Sun Pharma's expensive rating of 35.41. The stock has underperformed compared to the Sensex, with a year-to-date return of -36.18% against the Sensex's 6.81%, reinforcing the notion that the stock may be fairly valued given its recent performance and relative ratios.